Teleflex (NYSE:TFX) Stock Bumped Up to Strong-Buy by Zacks Research

Zacks Research upgraded shares of Teleflex (NYSE:TFX) from a hold rating to a strong-buy rating in a report released on Thursday morning,Zacks reports.

A number of other equities analysts have also commented on TFX. Piper Sandler reissued an “overweight” rating and issued a $169.00 price objective (up from $160.00) on shares of Teleflex in a research note on Friday, August 7th. Wall Street Zen upgraded Teleflex from a “sell” rating to a “hold” rating in a research note on Sunday, August 9th. Needham & Company LLC lifted their price target on Teleflex from $159.00 to $170.00 and gave the company a “buy” rating in a report on Tuesday, August 25th. Truist Financial upped their price target on shares of Teleflex from $143.00 to $150.00 and gave the stock a “hold” rating in a research report on Monday, August 10th. Finally, BMO Capital Markets started coverage on shares of Teleflex in a research report on Wednesday, July 8th. They issued an “outperform” rating and a $159.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Teleflex currently has an average rating of “Moderate Buy” and a consensus price target of $152.90.

Teleflex Stock Performance

NYSE:TFX opened at $122.44 on Thursday. The stock has a market capitalization of $5.19 billion, a P/E ratio of -5.26, a price-to-earnings-growth ratio of 0.80 and a beta of 0.82. The company has a current ratio of 2.60, a quick ratio of 2.12 and a debt-to-equity ratio of 0.94. Teleflex has a 1 year low of $100.18 and a 1 year high of $145.00. The firm has a 50 day moving average of $134.00 and a 200-day moving average of $128.54.

Teleflex (NYSE:TFX) last released its quarterly earnings results on Thursday, August 6th. The medical technology company reported $1.76 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.48. Teleflex had a positive return on equity of 11.93% and a negative net margin of 39.67%.The business had revenue of $570.33 million for the quarter, compared to analyst estimates of $559.59 million. During the same period in the prior year, the company earned $3.73 EPS. Teleflex’s revenue for the quarter was up 28.9% on a year-over-year basis. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. As a group, sell-side analysts anticipate that Teleflex will post 7.26 EPS for the current fiscal year.

Teleflex Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Friday, August 14th will be paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Friday, August 14th. Teleflex’s dividend payout ratio is -5.84%.

Institutional Trading of Teleflex

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TFX. Diamond Hill Capital Management LLC Investment Advisor acquired a new position in Teleflex during the 2nd quarter valued at about $39,467,000. Assenagon Asset Management S.A. acquired a new stake in shares of Teleflex during the 2nd quarter worth approximately $1,391,000. Fifth Third Bancorp grew its position in shares of Teleflex by 3,204.8% during the 1st quarter. Fifth Third Bancorp now owns 68,144 shares of the medical technology company’s stock worth $8,151,000 after buying an additional 66,082 shares during the period. Irenic Capital Management LP acquired a new stake in shares of Teleflex during the 1st quarter worth approximately $104,061,000. Finally, Mangrove Partners IM LLC bought a new stake in shares of Teleflex during the fourth quarter worth approximately $31,331,000. 95.62% of the stock is currently owned by institutional investors and hedge funds.

About Teleflex

Teleflex Incorporated is a global medical technology company that develops, manufactures and supplies specialty medical devices for hospitals, clinicians and other health care providers. Its products are designed to support procedures in areas including vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgery and urology.

The company’s portfolio includes Arrow branded vascular access and catheter products, airway management devices, regional anesthesia products, surgical instruments, interventional devices and urological products.